Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Añadir filtros








Intervalo de año
1.
Korean Journal of Clinical Pathology ; : 694-702, 1997.
Artículo en Coreano | WPRIM | ID: wpr-136108

RESUMEN

Among the causes of pure red cell aplasia, human parvovirus B19 has been shown to be cytotoxic to erythroid progenitor cells in the bone marrow associated with chronic hemolytic anemia with rapidly dividing erythroids and persistently to be suppression of erythropoiesis in immunocompromised individuals related with failure to produce neutralizing antibody to the virus. In a patient with hereditary spherocytosis presenting acute onset of reticulocytopenia during hospitalization, who had shown severe anemia and prodromal symptoms including fever, fatigue and dizziness, infection of parvovirus Bl9 was proven by the presence of IgM and IgG antibodies to parvovirus Bl9, the detection of viral DNA using PCR technique in her serum and the decreased erythroid cells, especially late normoblasts in bone marrow, Also in the other who was diagnosed as hereditary elliptocytosis and complained of fever, headache, abdominal pain and diarrhea, an episode of reticulocytopenia and the nearly absence of late normoblasts in the bone marrow were observed. IgM antibodies to parvovirus Bl9 and the viral DNA were detected in her serum, too.


Asunto(s)
Humanos , Dolor Abdominal , Anemia , Anemia Hemolítica , Anticuerpos , Anticuerpos Neutralizantes , Médula Ósea , Diarrea , Mareo , ADN Viral , Eliptocitosis Hereditaria , Eritroblastos , Células Eritroides , Células Precursoras Eritroides , Eritropoyesis , Fatiga , Fiebre , Cefalea , Hospitalización , Inmunoglobulina G , Inmunoglobulina M , Parvovirus B19 Humano , Parvovirus , Reacción en Cadena de la Polimerasa , Síntomas Prodrómicos , Aplasia Pura de Células Rojas
2.
Korean Journal of Clinical Pathology ; : 694-702, 1997.
Artículo en Coreano | WPRIM | ID: wpr-136105

RESUMEN

Among the causes of pure red cell aplasia, human parvovirus B19 has been shown to be cytotoxic to erythroid progenitor cells in the bone marrow associated with chronic hemolytic anemia with rapidly dividing erythroids and persistently to be suppression of erythropoiesis in immunocompromised individuals related with failure to produce neutralizing antibody to the virus. In a patient with hereditary spherocytosis presenting acute onset of reticulocytopenia during hospitalization, who had shown severe anemia and prodromal symptoms including fever, fatigue and dizziness, infection of parvovirus Bl9 was proven by the presence of IgM and IgG antibodies to parvovirus Bl9, the detection of viral DNA using PCR technique in her serum and the decreased erythroid cells, especially late normoblasts in bone marrow, Also in the other who was diagnosed as hereditary elliptocytosis and complained of fever, headache, abdominal pain and diarrhea, an episode of reticulocytopenia and the nearly absence of late normoblasts in the bone marrow were observed. IgM antibodies to parvovirus Bl9 and the viral DNA were detected in her serum, too.


Asunto(s)
Humanos , Dolor Abdominal , Anemia , Anemia Hemolítica , Anticuerpos , Anticuerpos Neutralizantes , Médula Ósea , Diarrea , Mareo , ADN Viral , Eliptocitosis Hereditaria , Eritroblastos , Células Eritroides , Células Precursoras Eritroides , Eritropoyesis , Fatiga , Fiebre , Cefalea , Hospitalización , Inmunoglobulina G , Inmunoglobulina M , Parvovirus B19 Humano , Parvovirus , Reacción en Cadena de la Polimerasa , Síntomas Prodrómicos , Aplasia Pura de Células Rojas
3.
Korean Journal of Clinical Pathology ; : 839-846, 1997.
Artículo en Coreano | WPRIM | ID: wpr-136076

RESUMEN

BACKGROUND: Autoimmune hemolytic anemias are characterized by autoantibodies recognizing antigens on the Individual's own red blood cells, resulting in immune- mediated hemolysis. Blood transfusions have been regarded as hazardous in patients with autoimmune hemolytic anemia (AIHA) because of potential intensification of hemolysis and a presumed high incidence of alloimmunization. METHODS: We examined the pretransfusion and posttransfusion hemoglobin levels in 6 patients with autoantibodies in their sera, which showed panagglutinations with all bloods tested in the compatibility testing. They received 'least' incompatible blood because of inability to find compatible blood. RESULTS: When we compared pretransfusion hemoglobin level with posttransfusion hemoglobin level, in 5 of 6 patients with AIHA, the hemoglobin levels were increased after red cell transfusion. 4 patient who did not respond to transfusion therapy initially had an increase in hemoglobin level after steroid treatment. Any signs or symptoms indicating hemolytic transfusion reaction were not observed ducting the transfusion period in all patients. CONCLUSIONS: The decision to transfuse in AIHA should consider multiple factors including the patient's clinical status, the potential benefit of transfusion, the potential response to other therapeutic modalities, but must never be regarded as contraindicated, even though the compatibility test may be strongly incompatible.


Asunto(s)
Humanos , Anemia Hemolítica , Anemia Hemolítica Autoinmune , Autoanticuerpos , Incompatibilidad de Grupos Sanguíneos , Transfusión Sanguínea , Transfusión de Eritrocitos , Eritrocitos , Hemólisis , Incidencia
4.
Korean Journal of Clinical Pathology ; : 839-846, 1997.
Artículo en Coreano | WPRIM | ID: wpr-136073

RESUMEN

BACKGROUND: Autoimmune hemolytic anemias are characterized by autoantibodies recognizing antigens on the Individual's own red blood cells, resulting in immune- mediated hemolysis. Blood transfusions have been regarded as hazardous in patients with autoimmune hemolytic anemia (AIHA) because of potential intensification of hemolysis and a presumed high incidence of alloimmunization. METHODS: We examined the pretransfusion and posttransfusion hemoglobin levels in 6 patients with autoantibodies in their sera, which showed panagglutinations with all bloods tested in the compatibility testing. They received 'least' incompatible blood because of inability to find compatible blood. RESULTS: When we compared pretransfusion hemoglobin level with posttransfusion hemoglobin level, in 5 of 6 patients with AIHA, the hemoglobin levels were increased after red cell transfusion. 4 patient who did not respond to transfusion therapy initially had an increase in hemoglobin level after steroid treatment. Any signs or symptoms indicating hemolytic transfusion reaction were not observed ducting the transfusion period in all patients. CONCLUSIONS: The decision to transfuse in AIHA should consider multiple factors including the patient's clinical status, the potential benefit of transfusion, the potential response to other therapeutic modalities, but must never be regarded as contraindicated, even though the compatibility test may be strongly incompatible.


Asunto(s)
Humanos , Anemia Hemolítica , Anemia Hemolítica Autoinmune , Autoanticuerpos , Incompatibilidad de Grupos Sanguíneos , Transfusión Sanguínea , Transfusión de Eritrocitos , Eritrocitos , Hemólisis , Incidencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA